Post by Algaurizin

AI in Cancer Care at ASCO 2026: Innovation Hype Meets Equity Reality When Dr. Jo Chien, hematologist-oncologist at UCSF, framed AI as "a bridge between innovation and access" during a packed ASCO 2026 session, the metaphor captured both the promise and tension defining this year's meeting. Around her, companies showcased sophisticated AI tools promising to revolutionize cancer diagnosis, treatment selection, and clinical trial matching. Yet behind the demonstrations lay unresolved questions: Will these technologies actually reach underserved patients, or will they widen existing disparities? ASCO 2026 (May 29–June 2, Chicago) marked a watershed moment for artificial intelligence in oncology, not because of breakthrough algorithms, but because the field is finally confronting the gap between technical capability and real-world implementation. What Was Actually Demonstrated at ASCO 2026 The AI showcase extended beyond buzzwords to concrete clinical applications. Tempus, the precision medicine company combining genomic sequencing with AI, demonstrated its diagnostic intelligence platform and generative AI assistant Tempus One, which now serves thousands of oncologists with voice-and-text access to patient data. The platform connects real-world evidence to deliver actionable insights in real-time, according to company presentations. Qure.ai highlighted its FDA-cleared imaging biomarkers, with 26 total FDA clearances across 9 products for X-ray and CT imaging. The company's qXR system reads chest X-rays in 20 seconds, detecting 29 conditions simultaneously with 95–100% accuracy for lung cancer detection versus 74% for traditional methods. Their retrospective US study showed Qure.ai's FDA-cleared qXR-LN identified missed lung nodules in chest X-rays taken years before diagnosis—a critical capability for early detection. The company also demonstrated AI-powered clinical trial cohort identification capabilities at their ASCO 2026 booth. The Patient Access Argument: Company Claims vs. Reality Companies positioning AI tools at ASCO 2026 uniformly emphasized access expansion. Tempus described its platform as enabling "real-time, actionable insights to physicians" regardless of practice setting. Qure.ai's messaging focused on "driving stage shift through proactive, data-driven patient care". The ASCO Guideline Assistant, launched in partnership with Google Cloud using Vertex AI and Gemini models, promises faster access to evidence-based clinical guidelines for oncology professionals. The Equity Question: Does AI Reduce or Widen Disparities? This is where ASCO 2026's optimism meets uncomfortable reality. The society's 2024 Guiding Principles for Responsible AI Use explicitly include "Equity and Fairness" as a core principle, stating that "developers and users of AI should protect against bias in AI model design and use and ensure access to AI tools in application". Implementation Realities: Workflow Integration and Administrative Burden